Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Analysis of the Antigenic Profile of Uveal Melanoma Lesions with Anti-Cutaneous Melanoma-associated Antigen and Anti-HLA Monoclonal Antibodies

P. G. Natali, A. Bigotti, M. R. Nicotra, R. M. Nardi, A. Delovu, O. Segatto and S. Ferrone
P. G. Natali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Bigotti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. R. Nicotra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. M. Nardi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Delovu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Segatto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Ferrone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published March 1989
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The reactivity of 12 surgically removed uveal melanoma lesions with monoclonal antibodies (MoAb) to 14 membrane-bound and 2 cytoplasmic cutaneous melanoma-associated antigens (MAA), to the 2 subunits of HLA Class I antigens and to the gene products of the HLA-D region was compared with that of cutaneous melanoma lesions and correlated with their histiotype. The membrane-bound determinants defined by the anti-Mr 92,000 and 45,000 MAA MoAb TP39.1, anti-Mr 110.000 MAA MoAb M111, anti-Mr 118,000 MAA MoAb TP36.1, anti-Mr 115,000 MAA MoAb 345.134, anti-ICAM-1 MoAb CL203.4 and anti-Mr 31,000 MAA MoAb M2590, and the cytoplasmic determinants defined by the anti-MAA MoAb 465.12 and 2G-10 display a distribution in uveal melanoma lesions similar to that in cutaneous melanoma lesions. On the other hand, the membrane-bound determinants defined by the anti-Mr 100,000 MAA MoAb 376.96, anti-9-O-acetyl-GD3 ganglioside MoAb ME311 and anti-GD2-GD3 ganglioside MoAb ME361 were not detected in the uveal melanoma lesions tested. Furthermore, the membrane-bound determinants defined by the anti-GD3 MoAb R24, anti-nerve growth factor receptor MoAb ME20.4, anti-Mr 97,000 MAA MoAb 140.240, anti-carcinoembryonic antigen MoAb B1.1 and anti-HMW-MAA 149.53, 225.28, and 763.74 have a markedly lower expression in uveal than in cutaneous melanoma lesions. Incubation of uveal melanoma lesions with the pool of the MoAb 149.53, 225.28, and 763.74 recognizing distinct and spatially distant determinants of the HMW-MAA increased the intensity of staining of six lesions and stained four lesions which were not stained by the individual monoclonal antibodies. The distribution of HLA Class I antigens in uveal melanoma lesions resembles that in cutaneous melanoma lesions, since they are expressed in all the lesions of the mixed and epithelioid type but were not detected in those of the spindle type, i.e., the counterparts of nevocellular nevi. HLA Class II antigens are expressed with a lower frequency in uveal than in cutaneous melanoma lesions, since they were detected only in 2 of the 12 lesions. One of them is of the mixed type and the other one of the epithelioid type. Besides HLA antigens the determinants defined by the anti-carcinoembryonic MoAb B1.1, anti-ICAM-1 MoAb CL203.4, and anti-GD3 MoAb R24 displayed a differential distribution in the different histiotypes of uveal melanoma, since they are preferentially expressed in lesions of the mixed and epithelioid type.

Footnotes

  • ↵1 This work was supported by the CNR Progetto Finalizzato Oncologia No. 870155944, by Associazione Italiana per la Ricerca sul Cancro, by the Italian Ministry of Public Health, and by NIH Grants AI21384, CA37959, and CA39559.

  • ↵2 To whom requests for reprints should be addressed.

  • Received June 29, 1988.
  • Revision received November 4, 1988.
  • Accepted November 10, 1988.
  • ©1989 American Association for Cancer Research.
PreviousNext
Back to top
March 1989
Volume 49, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Analysis of the Antigenic Profile of Uveal Melanoma Lesions with Anti-Cutaneous Melanoma-associated Antigen and Anti-HLA Monoclonal Antibodies
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Analysis of the Antigenic Profile of Uveal Melanoma Lesions with Anti-Cutaneous Melanoma-associated Antigen and Anti-HLA Monoclonal Antibodies
P. G. Natali, A. Bigotti, M. R. Nicotra, R. M. Nardi, A. Delovu, O. Segatto and S. Ferrone
Cancer Res March 1 1989 (49) (5) 1269-1274;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Analysis of the Antigenic Profile of Uveal Melanoma Lesions with Anti-Cutaneous Melanoma-associated Antigen and Anti-HLA Monoclonal Antibodies
P. G. Natali, A. Bigotti, M. R. Nicotra, R. M. Nardi, A. Delovu, O. Segatto and S. Ferrone
Cancer Res March 1 1989 (49) (5) 1269-1274;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • Down-regulation by Interleukin 4 of Activation of Human Alveolar Macrophages to the Tumoricidal State
  • Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus
  • Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Show more Basic Sciences

Articles

  • Down-regulation by Interleukin 4 of Activation of Human Alveolar Macrophages to the Tumoricidal State
  • Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus
  • Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement